English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/62149
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients

AuthorsRivero, Antonio; Torres-Cornejo, Almudena; Ruiz-Valderas, Rosa; Gutiérrez Valencia, Alicia
Issue Date2012
PublisherPublic Library of Science
CitationPLoS ONE 7 (2012)
AbstractBackground: The aim of the study was to analyze the different impact of standard and low-dose Peg-IFN-α2a/RBV therapies on HCV viral decline in HIV/HCV genotype 3 co-infected patients during the first weeks of treatment. Methods: Plasma HCV viral decline was analyzed between baseline and weeks 1, 2 and 4 in two groups of treatment-naïve HCV genotype 3 patients with HIV co-infection. The Standard Dose Group (SDG) included patients who received Peg-IFN at 180 οg/per week with a weight-adjusted dose of ribavirin; Low-Dose Group (LDG) patients received Peg-IFN at 135 οg/per week with 800 mg/day ribavirin. The effect of IL28B genotype on HCV viral decline was evaluated in both groups. HCV viral decline was analyzed using a multivariate linear regression model. Results: One hundred and six patients were included: 48 patients in the SDG and 58 in the LDG. HCV viral decline for patients in the LDG was less than for those in the SDG (week 1:1.72±0.74 log 10 IU/mL versus 1.78±0.67 log 10 IU/mL, p = 0.827; week 2:2.3±0.89 log 10 IU/mL versus 3.01±1.02 log 10 IU/mL, p = 0.013; week 4:3.52±1.2 log 10 IU/mL versus 4.09±1.1 log 10 IU/mL, p = 0.005). The linear regression model identified the Peg-IFN/RBV dose as an independent factor for HCV viral decline at week 4. Conclusions: Our results showed that HCV viral decline was less for patients in the low-dose group compared to those receiving the standard dose. Until a randomized clinical trial is conducted, clinicians should be cautious about using lower doses of Peg-IFN/RBV in HIV/HCV genotype 3 co-infected patients. © 2012 Rivero-Jurez et al.
Identifiersdoi: 10.1371/journal.pone.0048959
issn: 1932-6203
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
journal.pone.0048959.pdf232,3 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.